Also, 10.5% (6/57) and 12.3% (7/57) of BTC patients have an identified mutation in the extracellular domain (ECD) of EGFR (L443Q, S464P, K467stop, N468D, G482E, G482R, L469S) as new mutations and in the tyrosine kinase domain (TKD) of EGFR (L707S, V786M, L788H, G810S, G824S, D837N T854I, D855N), respectively; 50%, 16.7%, and 33.3% of mutated BTC were detected in patients with ICC, ECC, and GBC, respectively. The gene discussed is EGFR; the disease is intrahepatic cholangiocarcinoma.